Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease

NCT02768532 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

47

Enrollment

OTHER

Sponsor class

Stopped low inclusion rates

Conditions

Crohn Disease

Interventions

DRUG: Vedolizumab

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Collaborators

[object Object]
[object Object]